We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

121 hedge funds and large institutions have $1.29B invested in Lexicon Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more call options, than puts

Call options by funds: $4.86M | Put options by funds: $2.62M

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

37% more capital invested

Capital invested by funds: $940M → $1.29B (+$351M)

22% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 37

1.11% less ownership

Funds ownership: 103.95% → 102.84% (-1.1%)

4% less funds holding

Funds holding: 126 → 121 (-5)

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

Holders
121
Holders Change
-5
Holders Change %
-3.97%
% of All Funds
2.77%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
11
Increased
45
Reduced
37
Closed
15
Calls
$4.86M
Puts
$2.62M
Net Calls
+$2.25M
Net Calls Change
+$3.14M

Top Buyers

1
AG
Artal Group
Luxembourg
+$20.1M
2
Millennium Management
Millennium Management
New York
+$4.39M
3
BlackRock
BlackRock
New York
+$2M
4
PCM
Price Capital Management
Louisiana
+$1.38M
5
CLM
ClearBridge LLC (Maryland)
Maryland
+$1.31M

Top Sellers

1
UIM
USS Investment Management
United Kingdom
-$22.6M
2
State Street
State Street
Massachusetts
-$6.86M
3
TCM
Tekla Capital Management
Massachusetts
-$1.98M
4
PA
Pinnacle Associates
New York
-$1.19M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
101
Bank of Montreal
Ontario, Canada
$18K +$10.6K +1,034 +253%
CLM
102
ClearBridge LLC (Maryland)
Maryland
$15.6K +$1.31M +127,800 +11%
PCM
103
Prelude Capital Management
New York
$14K +$12.3K +1,200 New
Nisa Investment Advisors
104
Nisa Investment Advisors
Missouri
$9K +$1.23K +120 +19%
PIA
105
Piedmont Investment Advisors
North Carolina
$9K +$7.67K +750 New
FHA
106
Flagship Harbor Advisors
Massachusetts
$9K +$7.9K +772 New
Daiwa Securities Group
107
Daiwa Securities Group
Japan
$7K – – –
Royal Bank of Canada
108
Royal Bank of Canada
Ontario, Canada
$6K -$7.32K -716 -60%
HNB
109
Huntington National Bank
Ohio
$5K – – –
AG
110
Advisor Group
Arizona
$3K – – –
LJHT
111
Laurie J. Hall Trustee
$3K – – –
ASN
112
Advisory Services Network
Georgia
$2K – – –
GRP
113
Global Retirement Partners
California
$2K – – –
YWP
114
YorkBridge Wealth Partners
New York
$2K – – –
ClearBridge Investments
115
ClearBridge Investments
New York
$2K +$113 +11 +9%
US Bancorp
116
US Bancorp
Minnesota
$2K +$1.31K +128 New
SEI Investments
117
SEI Investments
Pennsylvania
$1K -$1.2K -117 -62%
Simplex Trading
118
Simplex Trading
Illinois
$1K -$256 -25 -19%
HCM
119
Highlander Capital Management
New Jersey
$1K +$430 +42 New
RFC
120
Regions Financial Corp
Alabama
$1K +$757 +74 New
UIM
121
USS Investment Management
United Kingdom
– -$22.6M -2,741,942 Closed
TCM
122
Tekla Capital Management
Massachusetts
– -$1.98M -231,054 Closed
EMG
123
Ellington Management Group
Connecticut
– -$471K -55,000 Closed
DCM
124
Dupont Capital Management
Delaware
– -$310K -36,202 Closed
RTS
125
Round Table Services
New Jersey
– -$185K -21,611 Closed
2 3 4
5
6

LXRX Hedge Fund Activity: Q2 2018 in Review

121 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2018, worth a combined $1.29B — up 37% from $940M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of LXRX and 11 opened new positions — a net loss of 4 holders — while 37 trimmed existing stakes and 45 added.

The largest buyer was Artal Group, adding an estimated $20.1M. The largest seller was USS Investment Management, exiting entirely with an estimated $22.6M sold.

  • 121 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2018, down from 126 in Q1 2018.
  • Funds reported $1.29B of Lexicon Pharmaceuticals stock for Q2 2018, up 37% quarter-over-quarter.
  • 11 funds opened new Lexicon Pharmaceuticals positions in Q2 2018 and 15 closed out, a net change of -4 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q2 2018 was Artal Group, an estimated $20.1M added.
  • The largest Lexicon Pharmaceuticals seller in Q2 2018 was USS Investment Management, an estimated $22.6M sold.

Based on aggregated 13F filings for Q2 2018.